The Iliac/SFA/Popliteal Center

Filter Your Results

 

News

 

Spectranetics’ Stellarex DCB Takes Another Step Toward United States Market Approval With PMA Submission

November 2, 2016 -- The Spectranetics Corporation announced it has submitted the premarket approval (PMA) application to the US Food and Drug Administration for its Stellarex …

Complexity of SFA Disease Is Driving the Need for Dual Therapy

Prof. Thomas Zeller, MD

October 2016—A discussion of potential differential indications for drug-eluting devices.

The Future of Antiproliferative Therapies for Endovascular Interventions

Renu Virmani, MD, FACC

October 2016—Translational findings from the Ranger Paclitaxel-Coated Balloon data.

The Science Behind Local Drug-Delivery Technologies: The Benefit of Sustained Paclitaxel Release in the SFA

Juan F. Granada, MD, FACC

October 2016—Sustained drug release is key to maintaining biological effect.

Patterns of Restenosis: What Are the Data Telling Us?

With Michael R. Jaff, DO

October 2016— In your experience managing a major core laboratory and based on the latest clinical data, have you observed any differences in the pattern of restenosis between drug-coat…

Ranger Paclitaxel-Coated PTA Balloon Catheter Clinical Update

October 2016—Recent early data from two studies demonstrate the promise of the Ranger DCB.

Sustained Drug Release Optimizes Long-Term Outcomes

Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA

October 2016—Is the drug-eluting vascular stent a game-changer?

Are DCBs a Durable Solution?

Gary M. Ansel, MD

October 2016—A discussion of DCB durability and superiority in the context of 2-year data.

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.